Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to $1.5 million.

  • Eton Pharmaceuticals' Change in Accured Expenses rose 211.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 222.45%. This contributed to the annual value of $1.5 million for FY2024, which is 40.09% down from last year.
  • Eton Pharmaceuticals' Change in Accured Expenses amounted to $1.5 million in FY2024, which was down 40.09% from $2.5 million recorded in FY2023.
  • Eton Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $2.5 million during FY2023, with a 5-year trough of -$300,000 in FY2020.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.5 million (2024), whereas its average is $1.8 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 156.18% in 2020, then skyrocketed by 1,149.14% in 2022.
  • Eton Pharmaceuticals' Change in Accured Expenses (Yearly) stood at -$300,000 in 2020, then skyrocketed by 138.67% to $116,000 in 2021, then skyrocketed by 1,149.14% to $1.4 million in 2022, then surged by 70.95% to $2.5 million in 2023, then crashed by 40.09% to $1.5 million in 2024.